Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.27 (market cap $5.70B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 63 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| JNK | TVTX | |
|---|---|---|
Market Cap | $5.70B | $4.88B |
Volume | 1,722,684 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $67.52 |
52-Week Low | $92.25 | $26.79 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.66, down 0.29% amid a bearish technical outlook with selling pressure across moving averages and oscillators. The ETF shows consistent dividend payments of $0.53 but lacks fundamental ratio data. Recent market focus centers on rising bond yields and geopolitical tensions affecting high-yield bond markets.
Outlook remains cautious as technical indicators signal bearish momentum with RSI at overbought levels. Investment opportunities include steady dividend income, while risks involve sensitivity to interest rate hikes and broader bond market volatility. The ETF's performance is closely tied to credit market conditions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
